291 related articles for article (PubMed ID: 31655133)
1. β-Klotho gene variation is associated with liver damage in children with NAFLD.
Dongiovanni P; Crudele A; Panera N; Romito I; Meroni M; De Stefanis C; Palma A; Comparcola D; Fracanzani AL; Miele L; Valenti L; Nobili V; Alisi A
J Hepatol; 2020 Mar; 72(3):411-419. PubMed ID: 31655133
[TBL] [Abstract][Full Text] [Related]
2. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation.
Panera N; Meroni M; Longo M; Crudele A; Valenti L; Bellacchio E; Miele L; D'Oria V; Paolini E; Maggioni M; Fracanzani AL; Alisi A; Dongiovanni P
EBioMedicine; 2021 Mar; 65():103249. PubMed ID: 33640795
[TBL] [Abstract][Full Text] [Related]
3.
Ji F; Liu Y; Hao JG; Wang LP; Dai MJ; Shen GF; Yan XB
Aging (Albany NY); 2019 Sep; 11(18):7847-7858. PubMed ID: 31548436
[TBL] [Abstract][Full Text] [Related]
4. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
5. A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.
Wong BS; Camilleri M; Carlson PJ; Guicciardi ME; Burton D; McKinzie S; Rao AS; Zinsmeister AR; Gores GJ
Gastroenterology; 2011 Jun; 140(7):1934-42. PubMed ID: 21396369
[TBL] [Abstract][Full Text] [Related]
6. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
[TBL] [Abstract][Full Text] [Related]
8. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
[TBL] [Abstract][Full Text] [Related]
9. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.
Aaldijk AS; Verzijl CRC; Jonker JW; Struik D
Front Endocrinol (Lausanne); 2023; 14():1150222. PubMed ID: 37260446
[TBL] [Abstract][Full Text] [Related]
10. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
[TBL] [Abstract][Full Text] [Related]
11. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
12. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
13. Prolactin improves hepatic steatosis via CD36 pathway.
Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
[TBL] [Abstract][Full Text] [Related]
14. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
15.
Xu QY; Li H; Cao HX; Pan Q; Fan JG
Biomed Res Int; 2020; 2020():8869674. PubMed ID: 33294458
[TBL] [Abstract][Full Text] [Related]
16. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
[TBL] [Abstract][Full Text] [Related]
17. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
18. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
19. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
20. Role of neuropeptide Y gene variant (rs161477) in liver histology in obese patients with non-alcoholic fatty liver disease.
Aller R; López-Gomez JJ; Izaola O; Primo D; de Luis D
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):217-222. PubMed ID: 30691985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
